AR113036A1 - Conjugado de iduronato-2-sulfatasa - Google Patents

Conjugado de iduronato-2-sulfatasa

Info

Publication number
AR113036A1
AR113036A1 ARP180102143A ARP180102143A AR113036A1 AR 113036 A1 AR113036 A1 AR 113036A1 AR P180102143 A ARP180102143 A AR P180102143A AR P180102143 A ARP180102143 A AR P180102143A AR 113036 A1 AR113036 A1 AR 113036A1
Authority
AR
Argentina
Prior art keywords
iduronate
conjugate
immunoglobulin
same
sulfatase
Prior art date
Application number
ARP180102143A
Other languages
English (en)
Inventor
Se Chang Kwon
Sung Youb Jung
Jung Kuk Kim
Dae Jin Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR113036A1 publication Critical patent/AR113036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un conjugado en el que una región Fc de inmunoglobulina está unida a una enzima iduronato-2-sulfatasa a través de un resto de enlace polimérico no peptídico. Además, se proporciona un conjugado, un método para preparar el mismo, y una composición que incluye el mismo en el que un resto de enlace de polímero no peptídico está específicamente unido a una inmunoglobulina Fc.
ARP180102143A 2017-07-28 2018-07-30 Conjugado de iduronato-2-sulfatasa AR113036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170096470 2017-07-28

Publications (1)

Publication Number Publication Date
AR113036A1 true AR113036A1 (es) 2020-01-22

Family

ID=65040773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102143A AR113036A1 (es) 2017-07-28 2018-07-30 Conjugado de iduronato-2-sulfatasa

Country Status (6)

Country Link
US (1) US20200230253A1 (es)
JP (1) JP2020528756A (es)
KR (1) KR20190013615A (es)
AR (1) AR113036A1 (es)
TW (1) TW201920664A (es)
WO (1) WO2019022563A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201925236A (zh) 2017-10-02 2019-07-01 美商戴納立製藥公司 包含酶替代療法酶之融合蛋白
US20220184186A1 (en) * 2019-04-03 2022-06-16 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
CN113621057A (zh) * 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
JP6930052B2 (ja) * 2016-01-15 2021-09-01 サンガモ セラピューティクス， インコーポレイテッド 神経性疾患の処置のための方法および組成物

Also Published As

Publication number Publication date
TW201920664A (zh) 2019-06-01
WO2019022563A3 (ko) 2019-04-11
JP2020528756A (ja) 2020-10-01
KR20190013615A (ko) 2019-02-11
WO2019022563A2 (ko) 2019-01-31
US20200230253A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
AR120515A2 (es) Conjugado de enzimas terapéuticas
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CO2019009365A2 (es) Anticuerpos anti-lag3
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
EA201700546A1 (ru) Композит полипропилен - углеродное волокно
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
EA201700547A1 (ru) Армированная волокнами полимерная композиция
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
TR201906047T4 (tr) Göz dokusunun çapraz bağlanması.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
CR20190417A (es) Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas
ECSP12012105A (es) Antídotos de Anticoagulantes
BR112016029207A2 (pt) resinas de polietileno
BR112016015105A2 (pt) Conjugados var2csa-droga
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
CO2018013314A2 (es) Inmunglobulinas conjugadas con lisina
AR103428A1 (es) Anticuerpos de penetración celular